News | June 30, 2023
Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Ensitrelvir is an oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.
This innovative product eliminates two manufacturing steps and simplifies equipment setup
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Subscribe To Our Newsletter & Stay Updated
